Spyre Therapeutics (SYRE) used the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23 to detail its combination-therapy strategy across autoimmune indications, presenting early clinical readouts and outlining a development pipeline valued at $8.1 billion.
Shares have surged 474% over the past year, trading around $91.97 with analyst price targets ranging from $97 to $130. The three-and-a-half-year-old company carries a stock beta of 3 and operates a trial network spanning more than 35 countries and over 300 sites.
In inflammatory bowel disease, Spyre is conducting the SKYLINE study, a two-part trial in ulcerative colitis. Part A is an open-label monotherapy study evaluating alpha-4 beta-7, TL1A and IL-23 inhibitors, with roughly 40 patients per cohort. Part B incorporates combination and monotherapy arms sharing a single placebo group, with each monotherapy serving as a comparator for two combination regimens. Each monotherapy is tested at two doses, the higher matching the combination dose, in a population split roughly 50-50 between treatment-naive and refractory patients.
Early Part A data showed highly statistically significant improvements on the Robarts Histopathology Index, with three-point changes from baseline to week 12 among the strongest histopathology results reported in the field. TL1A and IL-23 performed in line with class expectations, while alpha-4 beta-7 demonstrated better efficacy than Entyvio at higher exposures. The company is targeting four-times-yearly dosing, either via intravenous loading followed by subcutaneous maintenance or all-subcutaneous induction.
In hidradenitis suppurativa, Spyre launched a TL1A monotherapy study and continues a TL1A plus IL-17A/F combination trial. The company said its TL1A candidate has approximately ten times greater potency and about three times the half-life of Merck's tulisokibart. A decision on advancing TL1A monotherapy is expected within weeks; the combination study will continue regardless.
For rheumatoid arthritis, data on SPY072 showed clear activity and excellent tolerability with safety similar to placebo, but responses were not strong enough to support monotherapy advancement. Spyre remains optimistic about psoriatic arthritis and axial spondyloarthritis, noting that IL-17 and IL-23 mechanisms tend to perform better in those indications, with data expected over the next few months.
On the competitive front, Johnson & Johnson's VEGA trial in ulcerative colitis — which combined two targeted therapies and nearly doubled remission rates versus monotherapy without meaningful safety trade-offs — was described as the "main starting gun" for combination therapy. J&J also runs the DUET trial in a more treatment-experienced population and the AFFINITY trial in psoriatic arthritis. Merck is expected to present Phase III tulisokibart data at the European Academy of Dermatology and Venereology meeting. AbbVie was noted as roughly neck and neck with Spyre on timing, using Skyrizi's on-body pump and a repurposed HIV drug for alpha-4 beta-7. Roche is advancing its own TL1A programs.
Spyre stated it views approximately a 10 percentage point improvement in clinical remission over current standards as the threshold required for the market to reward combination products.
